Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Anemia contributing to increased mortality and reduced quality of life in chronic kidney disease (CKD) patients. Among its causes, iron deficiency—both absolute and functional—plays a key role. Previous studies have suggested that reticulocyte hemoglobin content (CHr) is comparable to transferrin saturation (TSAT) as an indicator for iron supplementation in anemic CKD patients. This study aims to compare CHr and TSAT in predicting hemoglobin response to iron therapy among CKD patients.
This study was a sub-analysis of a previous randomized controlled trial involving 60 non-dialysis CKD patients with anemia, randomly assigned in a 1:1 ratio to receive either CHr-guided or TSAT-guided oral iron therapy. Pooled data from all participants were analyzed to evaluate correlations between these parameters and hemoglobin (Hb) changes over 12 weeks.
A total of 60 participants were included, of whom 70% were male, with a median age of 75 years (IQR, 66.5 to 79 years). The median estimated glomerular filtration rate (eGFR) was 28.7 ml/min/1.73m² (IQR, 22.2 to 40.18), and the baseline Hb was 11.4 g/dL (IQR, 10.7 to 12.1). After 12 weeks of iron therapy, patients in the CHr-guided group (CHr < 29 pg), showed a mean Hb increase of 0.39 ± 1.70 g/dl (p=0.422 compared with baseline), while those in TSAT guided group (T-sat <30%) showed an increase of 0.28 ± 1.46 g/dl (p=0.36). Exploratory analysis demonstrated a moderate positive correlation between changes in CHr and Hb response (r = 0.548, p-value < 0.001), whereas no correlation was found between changes in TSAT and Hb. (r = -0.036, p-value = 0.788). (Figure 1)
In non-dialysis CKD patients with iron deficiency, baseline CHr and TSAT showed comparable predictive value for hemoglobin response to iron supplementation. However, changes in CHr correlated more strongly with changes in Hb, suggesting that CHr may serve as a more reliable marker for monitoring and predicting of hematologic response to iron therapy.
